

## NCCN Dermatofibrosarcoma Protuberans V.1.2012 — Panel Meeting — August 1, 2011

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><b><u>DFSP-2</u></b></p> <p><b>Internal request:</b> Suggestion was made to add the option of imatinib mesylate for patients with recurrent disease who are unresectable.</p>	<p>Based on available data and discussion the panel consensus was to change the recommendation for the treatment of patients with recurrent disease to the following: “Imatinib mesylate in cases where <i>disease is unresectable</i> or unacceptable functional or cosmetic outcomes will occur”.</p>	<p>Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.</p>	18	0	0